Skip to content

Rapid Build of HIV Related Protective Barriers

Cohort Study on Appropriate Strategies of The Rapid Build of HIV Related Protective Barriers in Yunnan, China

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03852849
Enrollment
600
Registered
2019-02-25
Start date
2019-03-01
Completion date
2021-03-01
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Viral Suppression of HIV Infection

Brief summary

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Detailed description

Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy. This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated. The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy. Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .

Interventions

BEHAVIORALPersonal involved intervention strategies

Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.

DRUGThe dosage of 400mg EFV

The dosage of 400mg EFV will be used in the antiviral therapy.

Sponsors

Yunnan Center for Disease Control and Prevention
CollaboratorOTHER
Yunnan AIDS Care Center
CollaboratorOTHER
National Center for AIDS/STD Control and Prevention, China CDC
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* HIV-positive participants who received an newly diagnosed HIV infection within the study period * Having a current residential address inside of pilot site limits * Eighteen years old or above * HIV transmission is heterosexual contact

Exclusion criteria

* IDU * Having severe mental disorder

Design outcomes

Primary

MeasureTime frame
Viral suppression of HIV-infected patients12 months

Secondary

MeasureTime frame
Treatment coverage12 months

Countries

China

Contacts

Primary ContactZhao Yan, PHD
zhaoyan@chinaaids.cn+86-10-5338-0980

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 24, 2026